Clinical Trial Update: Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating GM.CD40L vaccine with CCL21 immunotherapy in lung cancer; completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Lung Cancer

Drugs mentioned

• CCL21 (CCL21)
• GM.CD40L vaccine (GM.CD40L vaccine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer, Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-05